In response to a series of lawsuits from the pharma industry, the US Centers for Medicare and Medicaid Services (CMS) have announced changes to upcoming Medicare drug pricing negotiations. The agency dialed back a confidentiality policy associated with the negotiations, a sticking point for some plaintiffs who claimed it violated their First Amendment rights.
According to Phil Taylor, “Now, CMS will release information about the negotiation when the explanation of the maximum fair price (MFP) of a drug is published, and drug companies may choose to publicly discuss the negotiation at their discretion. It will allow ‘additional opportunities for drug companies and members of the public to engage with CMS during the negotiation process.’”
To read more, click here.
(Source: Pharmaphorum, July 2nd, 2023)